Search company, investor...
IVERIC bio company logo

IVERIC bio

ivericbio.com

Stage

IPO | IPO

Total Raised

$116M

Date of IPO

9/25/2013

Market Cap

2.72B

Stock Price

21.03

About IVERIC bio

IVERIC bio operates as a biopharmaceutical company. The company develops treatments for patients with orphan inherited retinal diseases with significant unmet medical needs. It is based in New York City, New York.

Headquarters Location

One Penn Plaza Suite 3520

New York, New York, 10119,

United States

212-845-8200

Missing: IVERIC bio's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: IVERIC bio's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing IVERIC bio

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

IVERIC bio is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

15,535 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

IVERIC bio Patents

IVERIC bio has filed 21 patents.

The 3 most popular patent topics include:

  • Disorders of choroid and retina
  • Monoclonal antibodies
  • Diseases of the eye and adnexa
patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/21/2022

11/8/2022

Coupling reactions, Carbon-carbon bond forming reactions, Addition reactions, Substitution reactions, Rare diseases

Grant

Application Date

2/21/2022

Grant Date

11/8/2022

Title

Related Topics

Coupling reactions, Carbon-carbon bond forming reactions, Addition reactions, Substitution reactions, Rare diseases

Status

Grant

Latest IVERIC bio News

VIDEO: Emerging treatments promising for neovascular AMD

Jan 16, 2023

Healio Interviews Disclosures: Regillo reports relevant financial disclosures with 4DMT, Adverum, Allergan Annexon, Apellis, Astellas, Clearside, EyePoint, Genentech, Graybug, Gyroscope, Iveric Bio, Janssen, Kodiak, Lineage Cell Therapeutics, Merck, NGM, Notal, Novartis, Ocugen, Opthea, Regeneron, Regenxbio, Stealth BioTherapeutics, Théa and Zeiss. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact customerservice@slackinc.com . Back to Healio KOLOA, Hawaii — In this Healio Video Perspective from Hawaiian Eye 2023, Carl D. Regillo, MD, discusses promising treatments for neovascular AMD , as well as phase 3 data from the Archway trial. Regillo further discusses recent setbacks involving the port delivery system (Susvimo, Genentech) as well as recent accomplishments in the gene therapy space. Read more about

IVERIC bio Frequently Asked Questions (FAQ)

  • Where is IVERIC bio's headquarters?

    IVERIC bio's headquarters is located at One Penn Plaza, New York.

  • What is IVERIC bio's latest funding round?

    IVERIC bio's latest funding round is IPO.

  • How much did IVERIC bio raise?

    IVERIC bio raised a total of $116M.

  • Who are the investors of IVERIC bio?

    Investors of IVERIC bio include Novo Holdings, HBM Healthcare Investments, SV Health Investors and Clarus.

  • Who are IVERIC bio's competitors?

    Competitors of IVERIC bio include Adamas Pharmaceuticals, CoMentis, Hyperion Therapeutics, Neuronascent, iPierian and 12 more.

Compare IVERIC bio to Competitors

M
Metastatix

Metastatix is a pharmaceutical company based in Atlanta, GA. Founded in 2005, the company is developing and commercializing small- molecule drugs to treat severely debilitating or life-threatening diseases including cancer, HIV infection, and macular degeneration. Per the company, Metastatix has pioneered the development of a series of oral small-molecule CXCR4 inhibitors that have unprecedented biological activity in preclinical models. The company has licensed its technology from Emory University.

O
OTO Medicine

OtoMedicine, Inc. aims to become a provider of medicines to prevent, treat and cure hearing loss. Based on over two decades of research at the University of Michigan, the company's lead product, AuraquellTM, is a combination of micronutrients that significantly aims to reduce noise induced hearing loss (NIHL) suffered by individuals continually exposed to loud noise in their work or recreational activities.

N
NeoCytex BioPharma

NeoCytex BioPharmaceuticals develops therapeutics to promote the repair and rejuvenation of damaged tissues. The lead drug candidate NBI-18 is being developed for speeding up recovery from neurodegenerative (Parkinson's, Alzheimer's) and cerebrovascular diseases.

A
Altheos

Altheos, Inc. is an early-stage biopharmaceutical company focused on the identification and development of promising well-differentiated novel small molecule drugs for unmet medical needs. Altheos, Inc. was co-founded in 2009 by two experienced pharmaceutical drug development executives and entrepreneurs, Henry H. Hsu, M.D. and M. (Ken) Kengatharan, Ph.D. The company is headquartered in South San Francisco, California.

N
Neuraltus Pharmaceuticals

Neuraltus Pharmaceuticals is a privately-held biopharmaceutical company dedicated to developing and commercializing innovative therapeutics that address critical unmet needs for patients and physicians in the treatment of neurodegenerative diseases. The Company is collaborating with global ALS specialists and seeking input from patient advocacy organizations to help inform the clinical development path and better understand the needs of people affected by the disease.

E
Epiphany Biosciences

Epiphany Biosciences is focused on advancing new therapies for infectious disease. The founders include Fred Volinsky MD, Robert Gallo MD, David Myles Ph.D and Barry Selick Ph.D. Epiphany is located in San Francisco, California.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.